Veracyte | VCYT - Gross Profit On Sales

Stock Price
31.57
Daily Change
-1.10 -3.37%
Monthly
-3.69%
Yearly
4.36%
Q2 Forecast
31.28

Veracyte reported $101.97M in Gross Profit on Sales for its fiscal quarter ending in December of 2025.





Gross Profit On Sales Change Date
Agenus USD 34.2M 4.61M Dec/2025
Agilent USD 946M 44M Dec/2025
Anika Therapeutics USD 19.18M 3.6M Dec/2025
Arrowhead Research USD 256.47M 228.7M Sep/2025
Bruker USD 449.2M 69.8M Dec/2025
Heron Therapeutics USD 29.47M 3.17M Dec/2025
Illumina USD 759M 26M Dec/2025
Intrexon USD -297K 167K Jun/2024
Karyopharm Therapeutics USD 32.6M 63.38M Dec/2025
Laboratory Of America USD 993.2M 31.9M Dec/2025
Ligand Pharmaceuticals USD 155.28M 82.42M Sep/2025
Myriad Genetics USD 146.8M 3M Dec/2025
Rigel Pharmaceuticals USD 28.49M 7.01M Jun/2024
Roche Holding CHF 22.09B 10.04B Dec/2025
Sangamo BioSciences -2.39M 1.09M Jun/2024
Siemens EUR 8.1B 567M Sep/2025
Sonic Healthcare AUD 3.92B 3.14B Dec/2024
Thermo Fisher Scientific USD 4.64B 419M Dec/2025
Veracyte USD 101.97M 10.69M Dec/2025
Waters USD 557.42M 97.44M Dec/2025